Premium
Annual report of the C ommittee on G ynecologic O ncology, the J apan S ociety of O bstetrics and G ynecology
Author(s) -
Yamagami Wataru,
Aoki Daisuke
Publication year - 2015
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.12596
Subject(s) - stage (stratigraphy) , medicine , ovarian cancer , cervical cancer , endometrial cancer , cancer , gynecology , oncology , gastroenterology , biology , paleontology
The J apan S ociety of O bstetrics and G ynecology collects and analyzes annual data on gynecologic cancers from member institutions. Here we present the Patient Annual Report for 2012 and the Treatment Annual Report for 2006. Data on 7028 patients with cervical cancer, 8217 with endometrial cancer, 5140 with ovarian cancer and 1725 with ovarian borderline tumor for whom treatment was initiated in 2012 were summarized in the Patient Annual Report. Data on the prognosis of 2699 patients with cervical cancer, 3243 with endometrial cancer and 1898 with ovarian cancer for whom treatment was initiated in 2006 were analyzed in the Treatment Annual Report. In the Patient Annual Report for 2012, stage I accounted for 55.4%, stage II for 23.0%, stage III for 11.0% and stage IV for 10.6% of all patients with cervical cancer. Stage I accounted for 72.2%, stage II for 7.0%, stage III for 13.4% and stage IV for 7.3% of all patients with endometrial cancer. Stage I accounted for 43.1%, stage II for 9.2%, stage III for 29.7% and stage IV for 7.2% of all patients with ovarian cancer. In the Treatment Annual Report for 2006, the 5‐year overall survival rates for patients with cervical cancer were 92.9% for stage I , 74.6% for stage II , 55.3% for stage III and 24.3% for stage IV . The equivalent rates for patients with endometrial cancer were 96.3%, 92.7%, 80.6% and 35.8%, respectively; and those for patients with ovarian surface epithelial–stromal tumors were 90.6%, 82.9%, 48.7% and 40.9%, respectively.